tracellular fluid (ICF) accounts for approximately two-thirds of total body water. Potassium, phosphorus, magnesium, and protein compose the majority of the elements in the intracellular space. The extracellular fluid (ECF) is divided into the intravascular fluid (plasma) and interstitial fluid (lymph fluid, transcellular fluid). Of the one-third of total body water found in the extracellular compartment, 25% is located in the intravascular space and 75% is located in the interstitial space. Sodium and chloride are the primary electrolytes found in the extracellular compartment ( Figure 2 ).
Ⅺ Fluid Movement
Fluid movement between the intracellular and extracellular compartments is maintained by the cell wall, which functions as a semipermeable membrane. Through active and passive transport, electrolytes and water move between the ICF and ECF. The cell membrane is completely permeable to water, thus any condition that alters the osmotic pressure in either compartment will cause a redistribution of water. Electrolytes have an "osmotic potential," which refers to the affinity an electrolyte has for water-its ability to pull water into a compartment. Sodium and dextrose have high osmotic potentials, and movement of these solutes can result in major fluid shifts between the ICF and ECF.
Within the extracellular compartment, the electrolyte concentration is fairly similar between the interstitial fluid and intravascular fluid. The one main difference is the large amount of plasma proteins found in the intravascular space. Proteins (predominantly albumin) in the plasma exert an osmotic pressure that prevents fluid from leaving the intravascular space and exerts a "pull" from the interstitial space. This is referred to as the colloid osmotic pressure. Simultaneously, the volume of blood exerts a pressure within the blood vessel to exceed the pressure in the interstitial space. Hydrostatic pressure is the "pushing" force that is exerted on the compartment wall which causes water and electrolytes to move through the capillary wall into the interstitial space. Colloid osmotic pressure and hydrostatic pressure represent the "pull" and "push" required to maintain homeostasis between the interstitial and intravascular spaces.
Ⅺ Osmolality
Osmolality is the concentration of solute particles in solution related to the concentration of water molecules in solution. It is expressed as osmotic activity per volume of water. The number of osmotically actively particles within any given compartment is between 290 and 310 mOsm/L.
Ⅺ Tonicity
Tonicity refers to the fluid tension within the ECF or ICF and describes the relationship between the total solutes and water within these compartments. Tonicity is determined by fluid osmolality-the weight of particles in the compartment or solution that can attract fluid. When fluid tension of a compartment or solution is equal, the fluid is considered "isotonic." When a compartment or solution is more dilute, it is considered "hypotonic." Compartments or solutions that are more concentrated are said to be "hypertonic."
Ⅺ Evaluation of Volume Status

Physical Examination
In a vast majority of patients, careful physical examination will allow an assessment of whether a patient's volume status is normal, increased, or decreased. VOLUME OVERLOAD. Weight gain is the most sensitive and consistent sign of volume excess. 2 Gravity-dependent edema, another (Table 1) .
Laboratory Data
Laboratory studies may be helpful in confirming physical examination findings, especially when determining volume depletion.
volume depletion, aldosterone is secreted which causes reabsorption of sodium and chloride, resulting in decreased urinary sodium and chloride Ͻ20 mEq/L each. 3 Exceptions may occur with patients receiving diuretic therapy, salt-wasting disease states, and adrenal insufficiency. In these conditions, lab data may be misleading as the kidneys cannot maximally reabsorb sodium and chloride, despite the presence of hypovolemia, resulting in higher levels of urinary sodium and chloride. Urine chloride is more reflective of volume status in patients with sodium losses such as vomiting, certain diuretics, or those in ketoacidosis. The fractional excretion of sodium (FE Na ) is another marker for renal perfusion. FE Na is defined as the percentage of filtered sodium that is excreted in the urine. Under normal circumstances the FE Na is Ͻ1%. This indicates that Ͼ99% of filtered sodium is reabsorbed by the nephrons. In hypovolemic states, the FE Na is usually Ͻ1% and can be as low as 0.5%. 5 FE Na is most helpful in determining prerenal hypovolemia (FE Na Ͻ1%) from renal causes of acute oliguric renal failure (FE Na Ͼ2%).
A microscopic urinalysis may show hyaline casts and rare granular casts in patients with hypovolemia due to the relative concentration of the urine. Urine-specific gravity is the relative density of urine to water, a measurement of Ͼ1.020 and a urine osmolarity of 500 to 600 mOsm/L reflects volume depletion. Again, renal failure or diuretic therapy may impair the renal response to volume depletion, resulting in altered urine study results. 6 An osmolar gap is defined by the measured serum osmolality exceeding the calculated osmolality by Ͼ10 mOsm/kg. An osmolar gap can occur when significant quantities of unmeasured solutes are present in the serum, but not measured or accounted for in this formula (eg, mannitol, lipids, proteins, alcohols). Sodium is the primary determinant of ECF osmolality, and serum osmolality plays an important role in the evaluation of hypo-and hypernatremia.
Diagnostic Studies
INVASIVE DIAGNOSTIC STUDIES.
It is not uncommon for critically ill patients to have physical assessment findings and laboratory studies yield uncertain or contradictory data regarding volume status. This is especially true when there is evidence of volume overload in the interstitial or "third spaces" while there is evidence of intravascular volume depletion. Hemodynamic monitoring may be of value for these patients, although controversy exists over the validity, accuracy, and clinical implications of measurements obtained. However, hemodynamic monitoring may be beneficial to assess response to therapeutic interventions (ie, fluid boluses) and following trended data. (see Hemodynamic Assessment by Adams elsewhere in this issue.)
A central venous pressure (CVP) or right atrial pressure (RAP) is the measurement of pressure in the right atrium. The average CVP in a healthy, supine patient is 6 to 8 mmHg, but up to 10 mmHg may be accepted as normal in acutely ill patients. 7 Controversy exists over whether the measurement of CVP reliably indicates intravascular volume status. It is generally accepted that a reduced CVP will occur during and after acute volume loss. Therefore, a low CVP may reflect a volume deficit. However, CVP values depend on venous wall compliance, which can change rapidly to accommodate variations in blood volume. Therefore, it may be misleading to assess fluid volume status from a single CVP reading. CVP can be elevated in a variety of disease states: right heart failure, infarction, tricuspid regurgitation, increased intraabdominal pressure, pericardial tamponade, tension pneumothorax, positive pressure ventilation, or fluid overload. Thus, the finding of a low CVP may support the diagnosis of hypovolemia, but an elevated CVP does not necessarily support the diagnosis of volume overload. It is possible to have a CVP of 20 mmHg caused by any of the above disease states, and still have an underfilled right ventricle. CVP values may be most helpful in patients with single system organ failure (eg, cardiac) or uncomplicated acute blood loss. CVP readings may be useful during early resuscitation from acute injury with hypotension by following trends and response to fluid therapy. [7] [8] [9] [10] Pulmonary artery occlusion pressure (PAOP), also referred to as the pulmonary capillary wedge pressure (PCWP), measured with a pulmonary artery catheter allows estimation of left atrial pressure, which allows estimation of the left ventricular end diastolic pressure, an important determinant of cardiac output and indirect diagnostic tool to determine intravascular volume. A low PAOP may indicate hypovolemia, while an elevated PAOP may indicate impaired cardiac function. However, PAOP is influenced by factors such as blood volume, ventricular function, intrathoracic and intraabdominal pressures, vasopressors, vasodilators, and fluid therapy. There are no accepted high and low PAOP values to definitively diagnose hypovolemia versus cardiac dysfunction. A PAOP Ͻ10 mmHg may indicate an underfilled left ventricle (hypovolemia) while a PAOP Ͼ18 mmHg may suggest a full, distended, or noncompliant left ventricle. Again, factors such as valvular defects, ventricular defects, or pulmonary venous resistance (eg, chronic obstructive pulmonary disease) may elevate the PAOP, even in conjunction with an underfilled ventricle. [7] [8] [9] [10] Using the CVP or pulmonary artery catheter to evaluate a patient's response to fluid boluses may be helpful to determine intravascular volume. This is based upon the Frank-Starling relationship that describes the effect of volume loading on cardiac function.
Normally, as the ventricular volume is increased by intravenous fluid administration, the stroke volume will increase until a plateau is reached. The ventricle will reach its filling pressure based upon contractility, compliance, and afterload. Generally, an underfilled ventricle will show a slight increase in the CVP or PAOP with a constant or slight increase in the cardiac output/index in response to a fluid bolus. Once the ventricle is filled or at its plateau, small increments of fluid administration will result in greater increases in the PAOP or CVP and may show a decrease in the cardiac output. Administering fluid boluses and observing the cardiac output (or index), PAOP or CVP can help determine whether the ventricles require additional intravenous fluids or have reached filling potential. See Figure 3 for examples of fluid challenge algorithms. [11] [12] [13] [14] MINIMALLY INVASIVE DIAGNOSTIC STUDIES. Transthoracic echocardiography (TTE) can be used in the acute care setting to assess cardiac output, left ventricular (LV) systolic function, systolic pulmonary arterial pressure, wall motion, and ejection fraction. 15, 16 Clinically, the TTE can be used to evaluate the diastolic function and filling pressures of the LV, which can be useful in the acute care setting to determine responsiveness to fluid administration. 17 Limitations of TTE include operator dependence, a single view in time rather than continuous trended data, and expense. TTE images may have poor diagnostic quality in patients who are obese; have severe chronic obstructive pulmonary disease; are unable to be properly positioned; have thoracic incisions, chest tubes, or dressings; or are uncooperative. 15, 18 Transesophageal doppler uses sonography within the lumen of the esophagus to determine pressures within the descending thoracic aorta. The device measures the velocity of blood flow in the aorta and mathematically translates flow into stroke volume and cardiac output. Drawbacks to using this technology in acute care include the bulky size of the esophageal tube, and time-consuming measurements. Factors such as anemia, tachycardia, or a thick chest wall may interfere with the data values. Because this is a relatively new technology, its widespread use is currently limited. [19] [20] [21] [22] End-tidal carbon dioxide (CO 2 ) monitoring (PetCO 2 ) may also give diagnostic clues regarding volume status. During conditions of low cardiac output, expired CO 2 is reduced as a consequence of caused by decreased pulmonary perfusion. As circulating volume is restored, PetCO 2 should increase. 23 Lastly, an often overlooked and underutilized tool for assessing volume status in acute care patients is daily patient weight. Retention of one liter of fluid will result in a weight gain of approximately 2.2 pounds. 24 Obtaining a weight balance will also take into account insensible losses, such as those resulting from fever, mechanical ventilation, and open wounds.
Ⅺ Evaluation of Electrolytes
Serum electrolyte concentrations influence movement of fluid within and between body compartments. The major extracellular electrolytes are sodium, calcium, chloride, and bicarbonate. The most abundant cation is sodium; chloride is the most abundant an- ion. Potassium, magnesium, and phosphates are the major intracellular electrolytes, of which potassium is the most plentiful cation and phosphate is the most abundant anion. Serum electrolyte concentrations affect all metabolic activity in some way. Abnormal electrolytes may reflect fluid or acid-base imbalance, or renal, neuromuscular, endocrine or skeletal dysfunction. See Table 2 for common gastrointestinal electrolyte losses. 24, 25 Sodium Sodium affects body water distribution, promotes neuromuscular function, maintains acid-base balance, influences chloride and potassium levels, and helps the kidneys regulate water. Serum sodium disorders are always evaluated in relation to the patient's fluid status and may be associated with hypovolemic, hypervolemic, or isovolemic states. Normal serum sodium levels are 135 to 145 mEq/L. Maintenance of the plasma sodium concentration depends on two mechanisms: the ability of the kidneys to regulate water and an intact thirst mechanism with access to water. Arginine vasopressin or antidiuretic hormone (ADH) is the primary hormone that regulates water excretion. ADH is synthesized in the supraoptic and paraventricular nuclei of the hypothalamus. A 1 to 2% reduction in plasma osmolality inhibits ADH release, while a 1 to 2% increase in plasma osmolality (or a 7-10% decrease in blood pressure or volume) stimulates ADH release. The presence of ADH causes the luminal membranes of the cortical and medullary collecting tubules in the kidney to reabsorb water. Thus, both the hypothalamus and kidneys influence homeostatic sodium levels.
The most common cause of hypernatremia is dehydration-a pure water loss or hypotonic fluid loss from the body. Increased water loss may be caused by insensible losses such as sweat, burn injuries, wounds, or prolonged hyperventilation. Gastrointestinal losses include severe vomiting and diarrhea, and biliary, gastric, or fistula fluid losses. Central (neurogenic) and nephrogenic diabetes insipidus (DI) are both associated with hypernatremia from an inadequate replacement of urinary water losses. Central DI is associated with a decrease in ADH secretion, which causes a relatively dilute urine. It may be induced by trauma, pituitary surgery, hypoxemia, or ischemic encephalopathy. Nephrogenic DI is classified by normal ADH secretion in the presence of renal resistance to ADH's water-retaining effect. Hyperglycemia, osmotic diuretics (ie, mannitol, glycerol), and urinary concentrating defects can cause an increase in renal water loss, resulting in serum hypernatremia. Hypernatremia can also result from aldosteronism, steroid administration, or excessive sodium intake. Additionally, iatrogenic replacement of hypotonic losses with isotonic fluids can result in hypernatremia. Symptoms are most prominent with a significantly large or rapid (over hours) increase in the serum sodium concentration and are generally seen when the sodium exceeds 160 mEq/L 26 (Table 3) . Symptoms are often attributed to either the underlying volume depletion or a decrease in cellular volume, particularly cerebral cellular volume. Chronic hypernatremia is much less likely to cause symptoms due to the brain's ability to adapt slowly to volume loss with a solute gain to restore lost water. 26 This response normalizes the brain volume and accounts for the milder symptoms of chronic hypernatremia.
Treatment of hypernatremia starts with identification of the underlying cause. For patients with hypovolemic hypernatremia, free water replacement is required after replacement of the intravascular volume. Fluid therapy with 5% dextrose or hypotonic saline is guided by the calculation of the amount of free water deficit. This is calculated by:
Deficit (L) = 0.6 ϫ body wt (kg) ϫ ( [Serum Na divided by 140] -1) 27 The constant 0.6 represents the normal body proportion of water in healthy males. Use 0.5 in young females and elderly males and 0.4 in elderly females. Markedly obese patients may require even lower values, with replacement based on an adjustment body weight. Overly rapid sodium correction is potentially dangerous. Rapid reduction of the plasma sodium concentration may cause cerebral edema and lead to seizures, permanent neurologic damage, or death. Replacement of half of the free water deficit should be done in the first 24 hours, with the remainder being replaced over the next 24 to 72 hours. It is important to correct the sodium at a rate no greater than 0.5 mEq/L/hr or 10 to 12 mEq/L/day. 26 Therapy should stop when the serum sodium has reached 145 mEq/L. To calculate the estimated change in plasma sodium per liter of infused IV fluid:
⌬ serum Na + /L of IVF = (Infusate sodium in mEq/L -serum sodium) divided by ([0.6 x wt (kg)] +1) 26, 28 The sodium content of normal saline (0.9%) is 154 mEql/L and Ringer's lactate is 130 mEq/L. One-half normal saline (0.45%) has 77 mEq/L, one-quarter normal saline (0.2%) has 34 mEq/L, and 5% dextrose has 0 mEq/L. 26, 28 See Figure 4 for patient example.
Hyponatremia can be associated with hyper, hypo-, and isovolemic states. Hypervolemic hyponatremia is generally seen in edematous states. Causes include: congestive heart failure, cirrhosis, nephrotic syndrome, hypoalbuminemia, and hypothyroidism. Hypovolemic hyponatremia can be due to conditions causing volume depletion or losses where sodium losses are greater than volume loss. This includes gastrointestinal losses (vomiting, nasogastric suctioning, diarrhea, and fistula loss), diuretics, cerebral salt wasting, burn injury, excessive sweating, and third space fluid losses (eg, peritonitis, pancreatitis, bowel obstruction). Renal disease (eg, nonoliguric renal failure, renal tubular 29 Hyperosmolar hyponatremia may also be seen in patients with plasma hyperosmolality. This is most commonly seen with hyperglycemia, where the osmotic gradient across the cells facilitates water movement out of cells and into the plasma, with the resulting dilutional hyponatremia. The following formula can be used to determine an estimate appropriate sodium level in the presence of hyperglycemia:
(serum glucose mg/dL -100) ‫ן‬ 0.016 = expected change in serum sodium 27 This estimate varies with body size, falling more in smaller patients.
Pseudohyponatremia is caused by an increase in the plasma concentration of proteins (eg, immunoglobins in multiple myeloma) or lipids (eg triglycerides) which can transiently displace water in a given volume of plasma, but do not effect the sodium concentration. The result is an artificially low plasma sodium in relation to the percentage of plasma water.
Patients who develop severe hyponatremia (serum sodium below 120 mEq/L) or who develop hyponatremia over 24 hours are most likely to demonstrate signs and symptoms. 29 Signs of hyponatremia are listed in Table 4 . Treatment is directed toward first determining volume status. The amount of total body water excess can be calculated:
Water excess = (0.6 x wt [kg]) ϫ (1-[Serum Na divided by 140]) 27 Treatment for hypovolemic hyponatremia includes administration of isotonic fluids. Symptomatic patients may require hypertonic saline combined with furosemide to decrease rapid expansion of the ECF volume. Patients with asymptomatic hypervolemic hyponatremia require water restriction (Ͻ800 mL/day) and close observation. Patients with severe symptoms may require isotonic or hypertonic saline. Patients with cardiac disease may benefit from optimization of hemodynamics including the use of angiotensinconverting-enzyme (ACE) inhibitors which increase the excretion of water and improve hyponatremia. Loop diuretics also promote free water excretion. For nonhypotonic hyponatremia, treatment is directed at the underlying disorder and includes insulin for diabetics, and correction of water, potassium, and sodium deficits. Hemodialysis may be required for patients with impaired renal function. Sodium should not increase by more than 0.5 to 1 mEq/L/hr (or 8-10 mEq/day) and should stop when the serum sodium reaches 125 to 130 mEq/L. For patients with severe symptoms, initial correction may be 1 to 2 MEq/L for several hours. This rapid correction should be halted when the life-threatening symptoms have ceased, or the serum sodium reaches 125 mEq/L. 30 The calculation to determine the change in serum sodium per liter of intravenous fluid administered is the same as in hypernatremia (see Figure 4) . Hypertonic (5%) saline contains 855mEq/L and 3% hypertonic saline contains 513 mEq/L. Hypovolemic patients should be monitored closely. As the ECF volume is restored, the stimulus to release ADH will cease. This can cause a rapid diuresis and in- 
Potassium
Potassium is the major intracellular cation. It maintains cellular osmolarity equilibrium, muscle activity, enzyme activation and plays a role in acid-base balance. Normal serum potassium is 3.3 to 5.0 mEq/L while intracellular levels are generally 125 to 140 mEq/L. 29 Acute changes in plasma concentration can have dramatic effects on muscle contractility and nerve conduction. Hyperkalemia is often caused by either increased potassium release from cells or decreased urinary potassium excretion. Burns, crush injuries, tumor lysis, and massive hemolysis can cause transcellular redistribution of potassium out of the cell and into the vascular space. Beta-adrenergic blockade interferes with the potassium uptake by cells, although this usually results in minor elevations of serum potassium (Ͻ0.5 mEq/L) 29 in healthy patients. Potassium shifts from the cells into the ECF in the presence of acidosis. Serum potassium concentration rises approximately 0.7 mEq/L (range = 0.2-1.7) for every 0.1 pH unit decrease during acidosis. 29 The movement of potassium out of the cells during acidosis is primarily governed by chloride. The inability of chloride to permeate the cell membrane causes the transcellular exchange of hydrogen for potassium. Insulin deficiency often combined with hyperglycemia hyperosmolality frequently leads to hyperkalemia.
Impaired urinary potassium excretion can by caused by renal failure, hypoaldosteronism, adrenal insufficiency, potassium-sparing diuretics, and type-1 renal tubular acidosis. Excessive intake from supplements or blood transfusions may also cause hyperkalemia. Medications can cause hyperkalemia through potassium retention (eg, potassium-sparing diuretics, ACE inhibitors) or potassium redistribution (eg, succinylcholine). Digitalis toxicity can interfere with the Na + -K + -ATPase pump, resulting in potassium release from cells. Pseudohyperkalemia, an elevation of measured serum potassium, is due to potassium movement out of cells during or after the blood is drawn. Mechanical or technical causes of pseudohyperkalemia include hemolyzed blood sample, drawing blood above a site where potassium is infusing, and repeated clenching and unclenching of a fist during phlebotomy. 2 Additionally, potassium moves out of white blood cells and platelets after clotting has occurred. Patients with marked leukocytosis (Ͼ100,000 mm 3 ) or thombocytosis (Ͼ1,000,000 mm 3 ) may have an elevated measured serum potassium. 29 Symptoms of hyperkalemia include weakness, parasthesias, areflexia, ascending paralysis, nausea, and diarrhea. Patients may exhibit bradycardia, prolongation of the AV conduction leading to complete heart block, ventricular fibrillation, and asytole (see Table  5 ). 30 Treatment of hyperkalemia includes correcting factors that cause potassium to shift from the cells into the vascular space (eg, acidosis, insulin deficiency, hyperosmolality). Treatment of severe hyperkalemia includes intravenous calcium to stabilize the heart by reinstating the delta change required to move between resting and threshold membrane potential. Other therapies include intravenous insulin with glucose, albuterol, and sodium bicarbonate to drive potassium back into the cells, and Kayexalate, loop diuretics, and dialysis to remove potassium from the body. Hypokalemia is one of the most prevalent electrolyte abnormalities found in acute care. There are multiple causes of hypokalemia including renal losses from diabetes, acute tubular necrosis, diuresis, hypercalcemia, hypochloremia, and multifactorial polyuria. Other causes include aldosteronism, Cushing's syndrome, thiazide and loop diuretic use, postresuscitation, postmyocardial infarction, and hematologic malignancies. Gastric losses from vomiting, nasogastric suctioning, biliary drainage, diarrhea, fistulas, and postintestinal bypass surgery can lead to hypokalemia. Transcellular shifts of potassium can also occur, moving potassium from the plasma into the cells. Beta-adrenergic agonists (eg, albuterol, terbutaline, dopamine) can stimulate muscle cell membranes to move potassium into the cells. This effect changes the serum potassium by 0.5 to 1.0 mEq/L. Respiratory or metabolic alkalosis also promotes the transcellular shift of potassium and can have a variable and unpredictable effect on serum potassium. 29 Clinical signs and symptoms may be unreliable for assessment of hypokalemia and are generally not present until potassium levels fall below 3.0 mEq/L. 2 Patients receiving digitalis and patients with hepatic failure may exhibit symptoms with even mild hypokalemia. Symptoms are often related to skeletal, smooth, and cardiac muscle weakness (see Table 6 ).
Treatment depends on the severity of the potassium deficit, which must be estimated, because there is no correlation equation to determine plasma potassium concentration in relation to total body potassium stores. The loss of approximately 200 to 400 mEq/L body potassium will lower the serum potassium from 4 to 3 mEq/L, an additional 200 to 400 mEq/L loss will reduce the serum potassium to approximately 2 mEq/L. 29 Approximately 40 to 60 mEq/L of potassium administration (oral or intravenous) will increase the plasma concentration by 1 to 1.5 mEq. The serum potassium will increase by 2.5 to 3.5 mEq/L after administration of approximately 135 to 160 mEq/L potassium. Intravenous potassium is irritating to peripheral veins, therefore it should be administered in a concentration 20 to 40 mEq/L and can be given centrally in concentrations of 140 to 200 mEq/L (14-20 mEq/mL). 2 
Magnesium
Magnesium helps regulate intracellular metabolism, activates enzymes, affects metabolism of nucleic acids and proteins, helps transport sodium and potassium across the cell membrane, and influences intracellular calcium by its effect on the secretion of the parathyroid. Normal serum magnesium is 1.3 to 2.2 mEq/L. Hypermagnesemia can be caused by renal failure, overuse of magnesium-containing antacids or laxatives, adrenal insufficiency, or lithium toxicity. Signs and symptoms generally correspond with serum levels (see Table 7 ) and may include hyporeflexia, lethargy, flushing, EKG changes, respiratory depression, and hypotension. Treatment includes administration of calcium gluconate, hydration to enhance excretion, intravenous glucose and insulin, and hemodialysis for severe hypermagnesemia.
Hypomagnesemia can be caused by decreased intake, decreased intestinal absorption, diuretic therapy, chronic alcoholism, renal or metabolic disorders, gastric losses (nasogastric suctioning, severe diarrhea, intestinal fluids), other electrolyte abnormalities, and severe burns are just a partial list of the etiologies of magnesium loss. Symptoms include vertigo, ataxia, nystagmus, altered mentation, parasthesias, seizures, tetany, muscle spasms or tremors, weakness, hyperreflexia, hypertension, cardiac dysrthymias, nausea, constipation or ileus, and abdominal cramps. Treatment includes administering oral or intravenous magnesium, and correcting other electrolyte deficiencies. 
Calcium
Calcium helps regulate neuromuscular and enzyme activity, skeletal development, and blood coagulation. Calcium is measured as two forms, either bound to protein or as a positively charged ion ("ionized calcium"). Normal serum calcium is 8.9 to 10.1 mg/dL, assuming normal albumin levels. A decrease in albumin decreases the amount of total measured calcium in the plasma, but may not change the amount of active calcium, measured by the ionized calcium. The following formula is used to correct calcium in the presence of abnormal albumin:
Corrected total Ca = measured total Ca + 0.8 ‫ן‬ (4.0 -albumin) 33 Normal ionized calcium is 1.1 to 1.3 mmol/L. The ionized calcium accounts for approximately half of the total serum calcium concentration and is physiologically more relevant than the total calcium level. Ionized calcium represents the physiologically active portion of calcium in the body; therefore, calcium imbalances should be assessed and treated by the measured ionized calcium. 23 Hypercalcemia can be caused by parathyroid disorders, hyperthyroidism, pheochromocytoma, malignancy, renal failure, medications (calcium-containing agents, lithium, thiazide diuretics, and estrogens), prolonged immobilization, osteoporosis, and Paget's disease.
Clinical evaluation of the patient may reveal lethargy, stupor, coma, decreased muscle tone and strength, pathological fracture, anorexia, nausea or vomiting, constipation or ileus, abdominal pain, hypertension or hypovolemia, polyuria, renal insufficiency, interstitial nephritis, electrocardiogram (ECG) changes including a shortened Q-T interval, widened T-wave or dysrhythmias, or hyperchloremic acidosis. Treatment includes hydration, loop diuretics, and calcitonin.
Hypocalcemia can be related to hypoparathyroidism, vitamin D deficiency, chronic alcoholism, renal disease, sepsis, or hypothyroidism. Some medications can cause hypocalcemia including: bisphosphonates, calcitonin, furosemide, phenytoin, phenobarbitol, estrogens, cimetidine, radiocontrast agents, heparin, theophylline, and propylthioruacil. Ionized hypocalcemia is a common finding in ICU patients. Causes include: alkalosis, pancreatitis, sepsis, renal failure, and magnesium depletion. Calcium can also bind to the citrate preservative found in banked blood. This causes a transient hypocalcemia, which resolves when the citrate is metabolized by the liver and kidneys. Patients with renal or hepatic insufficiency will have a prolonged hypocalcemia.
Signs and symptoms of hypocalcemia may include peripheral numbness and tingling, muscle twitching, tetany, Chvostek's sign (facial muscle spasm) or Trousseau's sign (carpopedal spasm), seizures, confusion, hypotension, ECG changes (Q-T interval prolongation, ST segment changes, T wave changes), laryngospasm, bronchospasm, and papilledema. Treatment includes oral or intravenous calcium administration, magnesium administration, and oral phosphate binding agents for renal failure patients.
Phosphorus
Normal phosphorus levels range from 2.5 to 4.5 mg/dL. Phosphorus helps regulate calcium levels, and has a role in carbohydrate and lipid metabolism and acid-base balance.
Hyperphosphatemia is most often caused by renal failure. Other causes include: hypovolemia, lactic acidosis, severe hypothermia, tumor lysis syndrome, skeletal disease, intestinal obstruction, hypoparathyroidism, or acromegly. Patients are often asymptomatic. 
Ⅺ Assessment of Intravenous Fluids
Intravenous Fluid Administration
Intravenous (IV) fluid administration has several purposes: to replenish fluid compartments, replace renal and insensible losses, correct electrolytes, provide glucose calories, and correct/maintain acid-base balance. 23, 34 The composition of commonly used crystalloid intravenous fluids can be found in Table 8 .
Fluids are described in terms of their tonicity to plasma. Fluids with lower osmolality than plasma are considered hypotonic (ie, 5% dextrose in water). The body distribution of hypotonic solutions is similar to the distribution of water in the body. Thus, two-thirds of fluid given will disperse to the ICF, while onethird will disperse into the ECF. Figure 5 illustrates the example of D5W administration. Hypotonic fluids will not replace the vascular space and cannot be used for volume resuscitation. Because of the significant accumulation within the cellular space, dextrose is rarely used as an intravenous fluid independently, but can be combined with isotonic fluids to provide minimal glucose calories. D5W may also be used to treat hypernatremia or increased serum osmolality. 35 Isotonic fluids such as 0.9 normal saline (NS) and lactated ringers (LR) have a tonicity similar to plasma. When administered, these fluids will distribute into the extracellular space. The interstitial space is three times greater than the intravascular space, and fluid will be dispersed in this ratio (see Figure 5) . 37 There is a small fluid shift that occurs from the intracellular space to the extracellular space because NS is actually slightly more hypertonic than the ECF. Evidence suggests that after 1 hour of NS administration, approximately one-quarter of the isotonic fluid remains in the intravascular space. 36 Thus, isotonic solutions are the crystalloid of choice for fluid resuscitation or to replace intravascular losses. Combination crystalloids such as 5% dextrose with 0.9% normal saline will be dispersed as an isotonic fluid once the cells have utilized the glucose in the dextrose content. Similarly, although 5% dextrose with 0.45% normal saline is slightly hypertonic in solution, it becomes hypotonic as an infusion after the glucose is metabolized and will be distributed into the compartments as 50% free water and 50% isotonic saline. 24 For patients requiring fluid volume replacement, the choice of which isotonic fluid to use, NS or LR, is generally a matter of clinician preference. The sodium content in NS is higher than LR, thus NS may be a better option for hyponatremic patients. The sodium concentration of NS is 154 mEq/L while LR contains 140 mEq/L. It is thought that LR has an advantage over NS in acidotic patients for several reasons. First, the pH of LR is 6.5 while the pH of NS is 5.5. Additionally, the added lactate in LR is converted to bicarbonate in patients with normal liver function, further raising the serum pH. 36 Lastly, administration of large amounts of NS can result in a hyperchloremic-induced metabolic acidosis, while large amounts of LR may result in a metabolic alkalosis. 37 Hypertonic solutions (eg, 3% saline, 5% saline, 7.5% saline) are used occasionally for osmotic therapy or intravascular volume expansion. Administration of hypertonic solutions causes significant shifts from the intracellular space to the intravascular space; however, cellular dehydration is often the result of such fluid shifts. Hypertonic solutions should only be used with intensive hemodynamic and electrolyte monitoring and further research is needed to determine benefits and efficacy for the routine use of hypertonic solutions. 38.39 
Ⅺ Summary
Although hemodynamic monitoring and laboratory studies offer some assistance in determining intravascular volume, clinical examination remains a key component in the evaluation of fluid status. Controversy exists over the accuracy and validity of RAP and PAOP measurements; however, these parameters are often used as guides to determine the effect of fluid administration. Sodium is often a key component in determining fluid distribution within the body. Electrolyte abnormalities are a common finding in critically ill patients and need to be continuously evaluated. Isotonic intravenous fluids are the fluid of choice to replace intravascular volume losses. Although hypertonic solutions are effective for volume replacement, further research is required to determine benefits and safety of using these solutions routinely. 
